Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 3
Submit an article Journal homepage
692
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

Kelly N. Fitzgeralda Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7521-0825View further author information
ORCID Icon,
Andres E. Quesadab Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USAView further author information
,
Gottfried von Keudella Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Sandeep Raja Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Natasha E. Lewisb Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USAView further author information
,
Ahmet Doganc Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Gilles Sallesa Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
&
M. Lia Palombaa Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-5099-9156View further author information
ORCID Icon show all
Pages 751-754 | Received 09 Aug 2021, Accepted 28 Sep 2021, Published online: 23 Dec 2021

References

  • Teplyakov A, Obmolova G, Luo J, et al. Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold. Proteins. 2018;86(5):495–500.
  • Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-Directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–362.
  • Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988.
  • Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049–8057.
  • Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020; 4(16) :3850–3852.
  • Jilani I, O’Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102(10):3514–3520.
  • Klesmith JR, Wu L, Lobb RR, et al. Fine epitope mapping of the CD19 extracellular domain promotes design. Biochemistry. 2019;58(48):4869–4881.
  • Bruenke J, Barbin K, Kunert S, et al. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol. 2005;130(2):218–228.
  • Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
  • Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–1295.
  • Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539–3549.
  • Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10(5):702–723.
  • Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419–1431.
  • Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2017;130(Supplement 1):577–577.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.